RESOLUTE China RCT

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 400 participants.

Also called NCT01334268

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 400 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01334268
Main results
  • Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial JACC. Cardiovascular interventions, 2013-07 DOI, PubMed 23523240

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01334268. Randomized; single masking; primary purpose treatment. Start 2011-09 (actual); primary completion 2012-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
RESOLUTE China RCT
Acronym
R-China RCT
Condition
Ischemic Heart Disease
Condition
Stenotic Coronary Lesion
Condition
Cardiovascular Diseases
Condition
Arteriosclerosis
Intervention (Device)
Taxus Liberte Paclitaxel-Eluting Coronary Stent System
Intervention (Device)
Resolute Zotarolimus-Eluting Coronary Stent System
Lead sponsor
Medtronic Vascular (class: industry)

Record details

Record id
cardio:ct-nct01334268
Content hash
8d5f989cab786cc30055c35adf6f5f0b0781ad5cc5dd8dbdd55c9e118898831b